In practice, 111In-labeled cetuximab-F(ab')2 fragment imaging proved feasible to distinguish among HNSCC xenografts with differential EGFR expression, and monitor treatment response of radiotherapy and/or cetuximab treatment [17–19]. Here, EGFR is linked to head and neck squamous cell carcinoma.